Abstracts tagged "Animal models and scleroderma"

Abstract Number: 1908 • 2015 ACR/ARHP Annual Meeting
Macitentan Responsiveness Supports the Validity of a Murine Model of Pulmonary Hypertension in Scleroderma Associated with Altered Tgfbeta/BMPR2 Signalling
Emma C. Derrett-Smith¹, Vincent Sobanski², Adrian Gilbane², Sarah Trinder³, Yasmina Bauer⁴, Berengère Renault⁴, Marc Iglarz⁴, David Abraham⁵, Alan M. Holmes⁶ and Christopher P. Denton⁷, ¹Centre for Rheumatology and Connective Tissue Diseases,, UCL Division of Medicine, London, United Kingdom, ²UCL Division of Medicine, London, United Kingdom, ³Centre for Rheumatology and Connective Tissue Disease, UCL Division of Medicine, London, United Kingdom, ⁴Actelion Pharmaceuticals Ltd., Allschwil, Switzerland, ⁵Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁶Centre for Rheumatology and Connective Tissue Diseases, UCL Division of Medicine, London, United Kingdom, ⁷Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom
Background/Purpose: Pulmonary arterial hypertension (PAH) is an important complication of systemic sclerosis (SSc) that occurs in around 10% of cases. We have previously shown that…
Abstract Number: 649 • 2013 ACR/ARHP Annual Meeting
Altered BMP Signalling In a TGFβ Dependent Murine Model Of Scleroderma May Contribute To Development Of Pulmonary Arterial Hypertension
Adrian J Gilbane¹, Emma C. Derrett-Smith², Sarah Trinder³, Andrew Pearce⁴, Christopher P. Denton¹ and Alan M. Holmes⁵, ¹Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ²Centre for Rheumatology and Connective Tissue Diseases,, UCL Medical School Royal Free Campus, London, United Kingdom, ³Centre for Rheumatology and Connective Tissue Disease, UCL Medical School, London, United Kingdom, ⁴Respiratory Disease Area, Novartis, London, United Kingdom, ⁵Centre for Rheumatology and Connective Tissue Diseases, UCL, London, United Kingdom
Background/Purpose: Pulmonary arterial hypertension associated is an important complication of scleroderma (PAH-SSc) and has a poor prognosis compared to idiopathic (iPAH) or heritable (hPAH) forms…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].